Evidence map›Paper›PMID 36859593›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2023

Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: How to reduce equivocal and false positive studies.

Zainab Al Taha, Deniz Alibazoglu, Hani Sabbour, Ingy Romany, Haluk Alibazoglu, Sabahat Bokhari

Abstract read
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Appraisal of amyloidosis imaging practices in the Middle East/North Africa (PYP-MENA).European heart journal. Imaging methods and practice · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zainab Al TahaSheikh Shakhboot Medical City, Abu Dhabi, United Arab Emirates.ORCID 0000-0001-7528-8318
Deniz AlibazogluNorthwestern University, Chicago, IL, USA.ORCID 0000-0002-0868-5820
Hani SabbourCleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. hanisabbour1@icloud.com.ORCID 0000-0001-6960-1056
Ingy RomanyPfizer Gulf FZ-LLC, Dubai, United Arab Emirates.ORCID 0000-0003-0492-7893
Haluk AlibazogluCleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.ORCID 0000-0001-8607-9650
Sabahat BokhariRobert Wood Johnson Medical School - Rutgers University, New Brunswick, NJ, USA.ORCID 0000-0002-2773-4704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlanar and single-photon emission computed tomography (SPECT) nuclear imaging techniques with bone seeking radiotracers have been increasingly adopted for diagnosis of ATTR cardiac amyloidosis. However, inherent limitations of these techniques due to lack of anatomical landmarks have been recognized, with consequent high numbers of equivocal or false positive cases. SPECT/computed tomography (CT) fusion imaging offers a significant advantage to overcome these limitations by substantially reducing inaccurate interpretations. The authors present the results of a 3-year imaging quality improvement project that focused on reducing the high number of equivocal studies that were noted in the first two years of the amyloidosis program, comparing SPECT only to SPECT/CT fusion technique.

methodsA retrospective, systematic analysis of 176 patient records was performed to test the premise that SPECT/CT fusion imaging has the potential to reduce equivocal and false positive results.

resultsOf a total of 176 patients, 35 equivocal (19.8%), 32 (18.18%) strongly suggestive, and 109 (61.93%) not suggestive cases were identified. Recognizing that this was not consistent with the international data, the authors set out on a comprehensive quality assessment project to reduce the number of equivocal and false positive cases. In patients who initially underwent SPECT only (Group A; n = 78), the addition of SPECT/CT fusion resulted in the net reclassification of 73% of cases: 100% of equivocal cases (n = 35) were reclassified to not suggestive (n = 34) or strongly suggestive (n = 1). 73% of strongly suggestive cases (n = 30) were reclassified to not suggestive (n = 22) while 8 strongly suggestive cases were confirmed as true positives. 13 not suggestive cases remained negative after SPECT/CT fusion. In cases where SPECT/CT fusion was utilized from the beginning (Group B; n = 98), there were no reclassification of any of the cases when these cases were reprocessed as a control group.

conclusionAddition of SPECT/CT imaging reduces the false positive or equivocal studies and increases the diagnostic accuracy of the test. All false positive and equivocal studies were eliminated using the fusion technique. Utilizing the fusion imaging technique increases the spatial resolution, with the ability to localize myocardial uptake and accurately differentiate from blood pool, which is a major source of error.

Indexed as

AmyloidosisTomography, Emission-Computed, Single-PhotonHumansRetrospective StudiesSingle Photon Emission Computed Tomography Computed TomographyAmyloid heart diseaseCTImage ReconstructionSPECTTechnical

Identifiers

PMID36859593
PMCPMC10558365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.